Skip to content
IP + Technology Law
Home  »  News & Insights  »  News  »  Press Release

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States

October 20, 2014  | Joseph Mallon, Ph.D., Ryan E. Melnick, Ph.D., Kimberly J. Miller, Ph.D., Agnes Juang, Ph.D., Kerry S. Taylor, Ph.D., William Zimmerman, Rose M. Thiessen, Ph.D., Jing Liu, Jane Dai, Ph.D., Nathanael Luman, Ph.D., Victor C. Vassar and Vijay Gore, Ph.D.

Read the full press release here.

Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Joseph Mallon, Ph.D.
Partner
San Diego
joseph.mallon@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Ryan E. Melnick, Ph.D.
Partner
San Diego
ryan.melnick@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Kimberly J. Miller, Ph.D.
Partner
San Diego
kimberly.miller@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Agnes Juang, Ph.D.
Partner
Orange County
agnes.juang@knobbe.com
949-760-0404
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

William Zimmerman
Partner
Washington DC
bill.zimmerman@knobbe.com
202-640-6400
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Jane Dai, Ph.D.
Partner
San Diego
jane.dai@knobbe.com
858-707-4000
Knobbe Martens Client InterMune Receives FDA Approval for Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the United States Headshot

Nathanael Luman, Ph.D.
Partner
San Diego
nate.luman@knobbe.com
858-707-4000

Related Links

Industries

News & Insights

News
Sep 2026
Knobbe Martens Named a California Powerhouse by Law360
Publication highlights firm’s across-the-board strength in intellectual property law IRVINE, Calif., September 24, 2026 – Knobbe Martens is proud to announce that it has been named among Law360’s 2026 California...
News
Sep 2026
Knobbe Martens Again Named “Litigation Leader” by BTI Outlook
IRVINE, Calif., September 24, 2026 – Knobbe Martens is pleased to announce that the firm has again been named a “Litigation Leader” in the BTI Litigation Outlook, an annual report that...
News
Sep 2026
Knobbe Martens Takes Home Multiple Honors at 2026 OCCDL Awards Gala
Firm receives Legacy Award; Geetha Durairaj and Nefi Oliva named among Top Lawyers IRVINE, Calif., September 23, 2026 – Knobbe Martens is pleased to share that the firm and two...